Literature DB >> 12915312

Developmental expression of mouse muscleblind genes Mbnl1, Mbnl2 and Mbnl3.

Rahul N Kanadia1, Carl R Urbinati, Valerie J Crusselle, Defang Luo, Young-Jae Lee, Jeffrey K Harrison, S Paul Oh, Maurice S Swanson.   

Abstract

The RNA-mediated pathogenesis model for the myotonic dystrophies DM1 and DM2 proposes that mutant transcripts from the affected genes sequester a family of double-stranded RNA-binding factors, the muscleblind proteins MBNL1, MBNL2 and MBNL3, in the nucleus. These proteins are homologues of the Drosophila muscleblind proteins that are required for the terminal differentiation of muscle and photoreceptor tissues, and thus nuclear sequestration of the human proteins might impair their normal function in muscle and eye development and maintenance. To examine this model further, we analyzed the expression pattern of the mouse Mbnl1, Mbnl2, and Mbnl3 genes during embryonic development and compared muscleblind gene expression to Dmpk since the RNA pathogenesis model for DM1 requires the coordinate synthesis of mutant Dmpk transcripts and muscleblind proteins. Our studies reveal a striking overlap between the expression of Dmpk and the muscleblind genes during development of the limbs, nervous system and various muscles, including the diaphragm and tongue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12915312     DOI: 10.1016/s1567-133x(03)00064-4

Source DB:  PubMed          Journal:  Gene Expr Patterns        ISSN: 1567-133X            Impact factor:   1.224


  57 in total

Review 1.  Epigenetic changes and non-coding expanded repeats.

Authors:  Masayuki Nakamori; Charles Thornton
Journal:  Neurobiol Dis       Date:  2010-02-18       Impact factor: 5.996

2.  Transcription factors CTCF and Pax6 are segregated to different cell types during retinal cell differentiation.

Authors:  M Valeria Canto-Soler; Hu Huang; M Soledad Romero; Ruben Adler
Journal:  Dev Dyn       Date:  2008-03       Impact factor: 3.780

Review 3.  RNA protein interaction in neurons.

Authors:  Robert B Darnell
Journal:  Annu Rev Neurosci       Date:  2013-05-20       Impact factor: 12.449

4.  Mechanistic determinants of MBNL activity.

Authors:  Łukasz J Sznajder; Michał Michalak; Katarzyna Taylor; Piotr Cywoniuk; Michał Kabza; Agnieszka Wojtkowiak-Szlachcic; Magdalena Matłoka; Patryk Konieczny; Krzysztof Sobczak
Journal:  Nucleic Acids Res       Date:  2016-10-12       Impact factor: 16.971

5.  RAN Translation Regulated by Muscleblind Proteins in Myotonic Dystrophy Type 2.

Authors:  Tao Zu; John D Cleary; Yuanjing Liu; Monica Bañez-Coronel; Jodi L Bubenik; Fatma Ayhan; Tetsuo Ashizawa; Guangbin Xia; H Brent Clark; Anthony T Yachnis; Maurice S Swanson; Laura P W Ranum
Journal:  Neuron       Date:  2017-09-13       Impact factor: 17.173

6.  Muscleblind-like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis.

Authors:  Albert W Cheng; Jiahai Shi; Piu Wong; Katherine L Luo; Paula Trepman; Eric T Wang; Heejo Choi; Christopher B Burge; Harvey F Lodish
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

7.  MBNL1-RNA recognition: contributions of MBNL1 sequence and RNA conformation.

Authors:  Yuan Fu; Sreenivasa Rao Ramisetty; Nejmun Hussain; Anne M Baranger
Journal:  Chembiochem       Date:  2011-11-22       Impact factor: 3.164

Review 8.  Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy.

Authors:  N Muge Kuyumcu-Martinez; Thomas A Cooper
Journal:  Prog Mol Subcell Biol       Date:  2006

9.  Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins.

Authors:  Eric T Wang; Neal A L Cody; Sonali Jog; Michela Biancolella; Thomas T Wang; Daniel J Treacy; Shujun Luo; Gary P Schroth; David E Housman; Sita Reddy; Eric Lécuyer; Christopher B Burge
Journal:  Cell       Date:  2012-08-17       Impact factor: 41.582

Review 10.  Roles for RNA-binding proteins in development and disease.

Authors:  Amy E Brinegar; Thomas A Cooper
Journal:  Brain Res       Date:  2016-03-10       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.